Core Insights - Quoin Pharmaceuticals has successfully closed a private placement financing of up to $104.5 million, enhancing its financial position for future developments [7] - The company has secured Orphan Drug Designations for QRX003 for Netherton Syndrome in both the U.S. and Europe, which provides significant regulatory advantages [8] - QRX003 has received Fast Track Designation from the U.S. FDA, facilitating expedited development and review processes [10] Financial Highlights - As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027 [16] - The net loss for the quarter ended December 31, 2025, was approximately $4.3 million, compared to $2.3 million for the same period in 2024 [17] - For the full year 2025, the net loss was approximately $15.8 million, an increase from $9.0 million in 2024 [17] Clinical Development Progress - The pediatric study for QRX003 has been expanded to include 7 children, marking the largest cohort of this age group ever studied for Netherton Syndrome [9] - Positive nine-month data from a pediatric study indicates sustained skin healing and complete elimination of pruritus with no adverse events reported [9] - The company plans to submit an Investigational New Drug application to the FDA in the second half of 2026 for QRX003 [2] Regulatory Achievements - Quoin has applied for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which could enable accelerated regulatory review in Saudi Arabia [3] - An application for Orphan Drug Designation for QRX003 has also been submitted to Japan's Ministry of Health, Labour and Welfare, with confirmation of eligibility for both Orphan Drug Designation and Fast Track review [4] - The U.S. Rare Pediatric Disease Priority Review Voucher program has been extended, which could provide Quoin with a potential value of $150-$200 million if QRX003 is approved [5][6] Awareness Campaign - The NETHERTON NOW awareness campaign has surpassed 2 million video views and 24 million global impressions, highlighting the company's commitment to raising awareness for Netherton Syndrome [6]

Core Viewpoint - Kodiak Sciences' shares surged 52% following positive results from a late-stage study of its eye drug Zenkuda, which successfully met its primary endpoint in treating diabetic retinopathy [1][2]. Group 1: Drug Efficacy and Study Results - Zenkuda demonstrated that 62.5% of patients achieved at least a two-step improvement on a retinopathy severity scale at 48 weeks, compared to only 3.3% in the sham treatment group [2]. - Patients treated with Zenkuda experienced an 85% reduction in the risk of developing sight-threatening complications, such as progression to proliferative diabetic retinopathy [3]. - The drug was well tolerated, with no reported cases of vision-threatening conditions like inflammation of blood vessels or the eye [3]. Group 2: Regulatory and Market Implications - Kodiak Sciences plans to accelerate the submission for Zenkuda's approval to the U.S. Food and Drug Administration based on the study results [4]. - The drug showed consistent efficacy among patients, regardless of whether they were on GLP-1 medications, indicating a broad applicability [3].

Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional patent applica ...

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Accessibility StatementSkip Navigation ATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.(Nasdaq: ALZN) ("Alzamend"), a clinical- stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("B ...

Core Viewpoint - Pfizer's current dividend yield of 6.3% is significantly higher than most fixed-income alternatives, but the sustainability of this yield is in question due to concerning payout mechanics [2][4]. Dividend Snapshot - Annual Dividend is $1.72 per share with a quarterly dividend of $0.43 per share - The dividend yield stands at 6.3% - Pfizer has increased its dividend for 16 consecutive years from 2010 to 2026, with the most recent increase from $0.42 to $0.43 in 2025 - Pfizer is not classified as a Dividend Aristocrat due to a dividend cut in 2009 [3]. Payout Ratio Analysis - Pfizer paid $9.771 billion in dividends in FY2025 against a free cash flow of $9.076 billion, resulting in a shortfall of $695 million [4][8]. - The adjusted earnings payout ratio is 53.4%, which appears healthy, but the GAAP payout ratio is concerning at 126.5% due to $4.4 billion in non-cash impairment charges in Q4 2025 [5]. - The free cash flow payout ratio is at 107.7%, indicating a red flag for sustainability [5]. - Operating cash flow coverage is weak at 1.20x, with $11.705 billion in operating cash flow against $9.771 billion in dividends [5]. Debt and Liquidity Concerns - Total debt has risen to $67.4 billion, indicating an elevated debt level, while the debt-to-equity ratio is moderate at 0.78x [7]. - Liquid assets have decreased from $20.5 billion in 2024 to $13.6 billion in 2025, reflecting tighter balance sheet conditions compared to the COVID-era windfall years [9]. - Cash on hand is thin at $1.14 billion, contributing to concerns about liquidity [9].

Core Viewpoint - Pfizer's dividend safety is under scrutiny as its payout exceeds free cash flow, raising concerns about sustainability in the long term [2][3][7]. Financial Performance - In FY2025, Pfizer paid $9.771 billion in dividends against a free cash flow of $9.076 billion, resulting in a shortfall of $695 million [2][7]. - The GAAP payout ratio stands at 126.5%, indicating that the company is paying out more than it earns [2][8]. - The adjusted EPS payout ratio is 53.4%, which appears healthy, but is misleading due to non-cash charges affecting cash flow [2][8]. Debt and Liquidity - Total debt increased to $67.4 billion from $63.6 billion in 2024, while liquid assets decreased from $20.5 billion to $13.6 billion [9]. - Cash on hand is reported at $1.14 billion, indicating a tight liquidity position [9]. Dividend History - Pfizer has increased its dividend for 16 consecutive years, but the growth rate has been modest at around 2% to 3% annually [10]. - The company cut its dividend in half during the 2009 financial crisis, highlighting its willingness to adjust payouts under pressure [10]. Management Outlook - CEO Albert Bourla emphasized the focus on growth and pipeline catalysts over explicit dividend commitments during the Q4 2025 earnings call [12]. - The next earnings call on May 5, 2026, is expected to provide further insights into capital allocation and dividend sustainability [12][14]. Future Considerations - Pfizer's guidance for 2026 suggests an adjusted EPS of $2.80 to $3.00, which could lower the adjusted payout ratio below 65% if free cash flow recovers [13]. - The non-COVID portfolio showed a 6% growth for the full year, and the Seagen pipeline may offer long-term potential [13].

Core Insights - Plus Therapeutics, Inc. has appointed Ron Andrews, a veteran in the diagnostics industry, to its Board of Directors, which is expected to enhance the company's strategic direction and growth in the diagnostics sector, particularly for CNSide [1][2] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system, aiming to improve clinical outcomes [4] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery approaches [4] Leadership and Expertise - Ron Andrews brings over 35 years of experience in the diagnostics and molecular diagnostics industry, having held leadership roles in both large organizations and successful startups, and has been instrumental in raising over $600 million in capital and leading over $15 billion in exits [2] - His connections within the global diagnostics industry are expected to help Plus Therapeutics maximize the impact of its CNSide product on patients and drive shareholder value [2] Product Development - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary laboratory-developed tests, including CNSide, which identifies tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas [3] - The CNSide CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, improving the management of patients with leptomeningeal metastases [3]

Core Insights - Medicus Pharma Ltd. announced promising results from its Phase 2 SkinJect® study, indicating an overall response rate (ORR) of 80% in the 200µg cohort at Day 57, suggesting that the majority of treated lesions may avoid surgery [2][9] - The company aims to address a significant unmet medical need in non-melanoma skin cancer, particularly basal cell carcinoma (BCC), which is the most common cancer worldwide [7][18] Group 1: Clinical Data and Analysis - The 200µg cohort demonstrated a 73% clinical clearance rate at Day 57, indicating that approximately three out of four treated lesions may achieve visual resolution, potentially allowing many patients to defer or avoid immediate surgical intervention [8][11] - The study showed continued improvement in clearance rates from Day 29 to Day 57, supporting the notion of a durable treatment effect [12] - The dataset is considered decision-grade, supporting regulatory engagement and potential business partnerships [14] Group 2: Expert Insights and Perspectives - Dr. Babar Rao, a key opinion leader in dermatology, will provide an independent clinical interpretation of the dataset during the upcoming conference call, emphasizing the clinical significance of the findings in the context of the broader BCC treatment landscape [4][5] - The findings highlight a significant treatment backlog in BCC, where patients may face delays or undergo unnecessary procedures [5] Group 3: Strategic Positioning and Future Plans - The company is entering a catalyst-rich period, with plans to refine histological clearance endpoints and engage in discussions with the FDA regarding the registrational study design [14] - Medicus is also focusing on optimizing clinical trial design and exploring co-development opportunities, including a collaboration with Helix Nanotechnologies for mRNA vaccine development [19][20] - The company aims to position SkinJect as a minimally invasive alternative to surgery, addressing a large and underserved BCC patient population [14][18]

LB Pharmaceuticals Inc Developing Novel Therapies for Neuropsychiatric Disorders March 2026 1 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Ex ...

ile 77 ock Code : 1093) 2025 Results Presentation Mar. 2026 INNOVAT 2025 Updates Regulatory Updates New drugs approved (including new indications): Breakthrough Therapy Designations: Major Clinical Trial Progress IND approvals : North America (18) China (58) New pivotal clinical trials: From 2025 to the present, ■ BD transactions have been completed, with a billion US dollars. total amount of In 2025, the Licence fee income of billion vuan was booked in. 2 HD Envitan · Duoenvi - 1L Pancreatic cancer • Shanz ...